Incanthera
WHAT WE DO

A revolutionary oncology company

Incanthera is committed to the development of novel treatments for solid tumours (cancers), and licensing these to large pharmaceutical companies.

View what we do
SOL

Our most advanced program

The Company’s current lead product and focus is Sol, which the Company acquired in September 2018. Sol is a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers.

Find out more about Sol

Investors

Regulatory News

Latest News & Media

Press Coverage
May 27th, 2021

Shares Magazine Spotlight Profile

Read more
Webinar
May 19th, 2021

Shares Investor Evening - Webinar - Wednesday 19 May

Read more
News
June 23rd, 2021

Result of AGM 2021

Read more
View All News And Media